In addition, the delayed expression of select AD- and DAM1-markers (specifically CD33, Tyrobp, and Trem2) in the C5aR1-deficient Arctic mice suggests a delayed switch from disease-mitigating microglia to disease-enhancing microglia in mice lacking C5aR1. This evidence concerns the gene CD33 and Alzheimer disease.